Acne vulgaris is a skin condition characterized by an obstruction or inflammation of the oil glands, present on skin's surface, which are collectively termed as pilosebaceous units. The skin on face, back, and upper chest have a greater number of sebaceous follicles. Topical, systemic, or combination therapy can be used to treat acne, while mild and moderate acne are generally treated with topical therapy. Topical acne therapy has direct access to the target site (skin) prior to reaching the blood stream, thereby reducing the systemic adverse effects of delivery of drug via parenteral or oral routes. Oral antibiotics, on the other hand, are a crucial treatment for acne which have not improved with topical treatment and for inflammatory lesions, such as pustules, nodules, and papules. Due to their capability to improve dermal therapeutics by boosting therapeutic efficacy and lowering adverse effects, nanodelivery technologies, developed to address skin delivery difficulties, have been extensively investigated. The goal of this study is to go through the many types of pharmacological dosage forms that are available for the treatment of acne.
The present work comprised of the preparation of coated HPMC capsules of meloxicam microspheres in order to target the drug release in colon resulting in increased absorption and subsequent bioavailability. The meloxicam microspheres were developed in nineteen different batches using HPMC, combination of EC with HPMC, Eudragits (S100, RS100 and E100) in different drug and polymer ratios by solvent evaporation method. The formulation of different batches were examined by various studies i.e. percentage yield, surface morphology (SEM), particle size analysis, entrapment efficiency, drug compatibility with polymers using FTIR and in-vitro drug release determinations. The complex of meloxicam with β-cyclodextrin increased the solubility of the drug accompanying its in-vitro release. The microspheres filled HPMC capsules were coated with eudragit S100 which proved to be an effective method for drug targeting to the colon. A 22 factorial design showed that a very significant increase in release of the drug using polymers i.e. HPMC, E.C with HPMC, Eudragit S100, Eudragit RS100, Eudragit E100 could be obtained by the exclusive manipulation of two variables i.e. surfactant and polymer concentrations. The drug loaded microspheres showed percentage drug entrapment as 35.09-62.50% in A1-A4, 76.29-87.78% in B1-B4, 81.36-92.70% in S1-S4, 65.47-69.4% in RS1-RS4 and 68.91-78.08% in E1-E3. The pH 7.4 phosphate buffer and simulated colonic fluid were used for the in-vitro release tests. The best drug release profiles were seen with formulations A3, B2, RS1, S1 and E2 (containing different ratios of drug: polymer) coated with 15% (w/v) Eudragit S-100 solution.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.